Covid-19 drug from Singapore-based firm to enter final trials soon (Straits Times)

Trials for a potential monoclonal antibody treatment for COVID-19 – developed by Singapore-based biotechnology company Tychan – are being accelerated, with the third and final phase due to start in a few weeks’ time. Professor Ooi Eng Eong, Deputy Director of Duke-NUS' Emerging Infectious Diseases (EID) programme and a co-founder of Tychan, is quoted.